Vera Therapeutics
VERA
59 hedge funds and large institutions have $413M invested in Vera Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 6 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
7% more funds holding
Funds holding: 55 → 59 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.53% less ownership
Funds ownership: 79.66% → 77.12% (-2.5%)
10% less capital invested
Capital invested by funds: $459M → $413M (-$46.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$12.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.16M |
| 3 |
EP
Eversept Partners
New York
|
+$4.62M |
| 4 |
Walleye Capital
New York
|
+$4.15M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$2.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$33.6M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.82M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.58M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$2.3M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.98M |
VERA Hedge Fund Activity: Q4 2022 in Review
59 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q4 2022, worth a combined $413M — down 10% from $459M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new VERA positions and 6 closed out — a net gain of 4 holders — while 23 added to existing stakes and 13 trimmed.
The largest buyer was Millennium Management, adding an estimated $12.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $33.6M sold.
- 59 institutional investors held Vera Therapeutics (VERA) as of Q4 2022, up from 55 in Q3 2022.
- Funds reported $413M of Vera Therapeutics stock for Q4 2022, down 10% quarter-over-quarter.
- 10 funds opened new Vera Therapeutics positions in Q4 2022 and 6 closed out, a net change of +4 holders.
- The largest Vera Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $12.9M added.
- The largest Vera Therapeutics seller in Q4 2022 was RA Capital Management, an estimated $33.6M sold.
Based on aggregated 13F filings for Q4 2022.